- Previous Close
0.0000 - Open
122.0000 - Bid --
- Ask --
- Day's Range
122.0000 - 122.0000 - 52 Week Range
60.0000 - 127.0000 - Volume
30 - Avg. Volume
27 - Market Cap (intraday)
0 - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-0.00 - EPS (TTM)
-0.6700 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
www.intracellulartherapies.com860
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 23I.F
View MorePerformance Overview: 23I.F
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 23I.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 23I.F
View MoreValuation Measures
Market Cap
12.98B
Enterprise Value
12.08B
Trailing P/E
--
Forward P/E
158.73
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.00
Price/Book (mrq)
12.24
Enterprise Value/Revenue
19.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.97%
Return on Assets (ttm)
-6.96%
Return on Equity (ttm)
-8.58%
Revenue (ttm)
680.85M
Net Income Avi to Common (ttm)
-74.68M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
1B
Total Debt/Equity (mrq)
1.48%
Levered Free Cash Flow (ttm)
-63.55M